Edward Stites

Title(s)Assistant Adjunct Professor, Dermatology
SchoolVc-health Sciences-schools
Address9500 Gilman Drive #
La Jolla CA 92093
vCardDownload vCard

    Collapse Research 
    Collapse Research Activities and Funding
    Systems Approaches for Opening Therapeutic Windows
    NIH DP2AT011327Aug 15, 2020 - Jun 30, 2025
    Role: Principal Investigator
    Systems Biology of RAS and RAF Oncogenes and Personalized Medicine
    NIH K22CA216318Aug 1, 2017 - Jul 31, 2020
    Role: Principal Investigator

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. How often is each gene mutated within the cancer patient population? Mol Cell Oncol. 2022; 9(1):2065176. Mendiratta G, Jones MK, Stites EC. PMID: 35529901; PMCID: PMC9067461.
      View in: PubMed   Mentions:
    2. Identification of RAS mutant biomarkers for EGFR inhibitor sensitivity using a systems biochemical approach. Cell Rep. 2021 12 14; 37(11):110096. McFall T, Stites EC. PMID: 34910921; PMCID: PMC8867612.
      View in: PubMed   Mentions:
    3. Cancer gene mutation frequencies for the U.S. population. Nat Commun. 2021 10 13; 12(1):5961. Mendiratta G, Ke E, Aziz M, Liarakos D, Tong M, Stites EC. PMID: 34645806; PMCID: PMC8514428.
      View in: PubMed   Mentions:
    4. KRAS-Mutated, Estrogen Receptor-Positive Low-Grade Serous Ovarian Cancer: Unraveling an Exceptional Response Mystery. Oncologist. 2021 04; 26(4):e530-e536. Kato S, McFall T, Takahashi K, Bamel K, Ikeda S, Eskander RN, Plaxe S, Parker B, Stites E, Kurzrock R. PMID: 33528846; PMCID: PMC8018312.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    5. Mathematical Modeling to Study KRAS Mutant-Specific Responses to Pathway Inhibition. Methods Mol Biol. 2021; 2262:311-321. Stites EC. PMID: 33977486; PMCID: PMC8639139.
      View in: PubMed   Mentions:
    6. Discernment between candidate mechanisms for KRAS G13D colorectal cancer sensitivity to EGFR inhibitors. Cell Commun Signal. 2020 11 05; 18(1):179. McFall T, Schomburg NK, Rossman KL, Stites EC. PMID: 33153459; PMCID: PMC7643456.
      View in: PubMed   Mentions:
    7. Real-world data from a molecular tumor board demonstrates improved outcomes with a precision N-of-One strategy. Nat Commun. 2020 10 02; 11(1):4965. Kato S, Kim KH, Lim HJ, Boichard A, Nikanjam M, Weihe E, Kuo DJ, Eskander RN, Goodman A, Galanina N, Fanta PT, Schwab RB, Shatsky R, Plaxe SC, Sharabi A, Stites E, Adashek JJ, Okamura R, Lee S, Lippman SM, Sicklick JK, Kurzrock R. PMID: 33009371; PMCID: PMC7532150.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    8. The Interpretation of SARS-CoV-2 Diagnostic Tests. Med (N Y). 2020 12 18; 1(1):78-89. Stites EC, Wilen CB. PMID: 32864639; PMCID: PMC7441939.
      View in: PubMed   Mentions:
    9. A mechanism for the response of KRASG13D expressing colorectal cancers to EGFR inhibitors. Mol Cell Oncol. 2020; 7(2):1701914. McFall T, Stites EC. PMID: 32158916; PMCID: PMC7051129.
      View in: PubMed   Mentions:
    10. A systems mechanism for KRAS mutant allele-specific responses to targeted therapy. Sci Signal. 2019 09 24; 12(600). McFall T, Diedrich JK, Mengistu M, Littlechild SL, Paskvan KV, Sisk-Hackworth L, Moresco JJ, Shaw AS, Stites EC. PMID: 31551296; PMCID: PMC6864030.
      View in: PubMed   Mentions:
    11. Modeling cell line-specific recruitment of signaling proteins to the insulin-like growth factor 1 receptor. PLoS Comput Biol. 2019 01; 15(1):e1006706. Erickson KE, Rukhlenko OS, Shahinuzzaman M, Slavkova KP, Lin YT, Suderman R, Stites EC, Anghel M, Posner RG, Barua D, Kholodenko BN, Hlavacek WS. PMID: 30653502; PMCID: PMC6353226.
      View in: PubMed   Mentions:
    12. Proceedings of the fifth international RASopathies symposium: When development and cancer intersect. Am J Med Genet A. 2018 12; 176(12):2924-2929. Rauen KA, Schoyer L, Schill L, Stronach B, Albeck J, Andresen BS, Cavé H, Ellis M, Fruchtman SM, Gelb BD, Gibson CC, Gripp K, Hefner E, Huang WYC, Itkin M, Kerr B, Linardic CM, McMahon M, Oberlander B, Perlstein E, Ratner N, Rogers L, Schenck A, Shankar S, Shvartsman S, Stevenson DA, Stites EC, Stork PJS, Sun C, Therrien M, Ullian EM, Widemann BC, Yeh E, Zampino G, Zenker M, Timmer W, McCormick F. PMID: 30302932; PMCID: PMC6312476.
      View in: PubMed   Mentions: 3  Translation:HumansAnimalsCells
    13. Quantitative Systems Pharmacology Analysis of KRAS G12C Covalent Inhibitors. CPT Pharmacometrics Syst Pharmacol. 2018 05; 7(5):342-351. Stites EC, Shaw AS. PMID: 29484842; PMCID: PMC5980551.
      View in: PubMed   Mentions:
    14. A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients. J Gastrointest Oncol. 2017 Dec; 8(6):925-935. Ramanathan RK, Weiss GJ, Posner RG, Rajeshkumar NV, Jameson G, Aziz M, Hoering A, Bolejack V, Maitra A, Fulk M, Stites EC, Hlavacek WS, Gatalica Z, Xiu J, Hidalgo M, Von Hoff DD, Barrett MT. PMID: 29299351; PMCID: PMC5750179.
      View in: PubMed   Mentions:
    15. Use of mechanistic models to integrate and analyze multiple proteomic datasets. Biophys J. 2015 Apr 07; 108(7):1819-1829. Stites EC, Aziz M, Creamer MS, Von Hoff DD, Posner RG, Hlavacek WS. PMID: 25863072; PMCID: PMC4390817.
      View in: PubMed   Mentions:
    16. Cooperation between Noncanonical Ras Network Mutations. Cell Rep. 2015 02 10; 10(5):840. Stites EC, Trampont PC, Haney LB, Walk SF, Ravichandran KS. PMID: 30849858.
      View in: PubMed   Mentions:
    17. Cooperation between Noncanonical Ras Network Mutations. Cell Rep. 2015 Jan 20; 10(3):307-316. Stites EC, Trampont PC, Haney LB, Walk SF, Ravichandran KS. PMID: 25600866; PMCID: PMC4503519.
      View in: PubMed   Mentions:
    18. Allosteric activation of functionally asymmetric RAF kinase dimers. Cell. 2013 Aug 29; 154(5):1036-1046. Hu J, Stites EC, Yu H, Germino EA, Meharena HS, Stork PJS, Kornev AP, Taylor SS, Shaw AS. PMID: 23993095; PMCID: PMC3844432.
      View in: PubMed   Mentions: 109     Fields:    Translation:HumansAnimalsCells
    19. Chemical kinetic mechanistic models to investigate cancer biology and impact cancer medicine. Phys Biol. 2013 Apr; 10(2):026004. Stites EC. PMID: 23406820.
      View in: PubMed   Mentions:
    20. The response of cancers to BRAF inhibition underscores the importance of cancer systems biology. Sci Signal. 2012 Oct 16; 5(246):pe46. Stites EC. PMID: 23074264.
      View in: PubMed   Mentions:
    21. Genome-wide characterization of pancreatic adenocarcinoma patients using next generation sequencing. PLoS One. 2012; 7(10):e43192. Liang WS, Craig DW, Carpten J, Borad MJ, Demeure MJ, Weiss GJ, Izatt T, Sinari S, Christoforides A, Aldrich J, Kurdoglu A, Barrett M, Phillips L, Benson H, Tembe W, Braggio E, Kiefer JA, Legendre C, Posner R, Hostetter GH, Baker A, Egan JB, Han H, Lake D, Stites EC, Ramanathan RK, Fonseca R, Stewart AK, Von Hoff D. PMID: 23071490; PMCID: PMC3468610.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCells
    22. Specification, annotation, visualization and simulation of a large rule-based model for ERBB receptor signaling. BMC Syst Biol. 2012 Aug 22; 6:107. Creamer MS, Stites EC, Aziz M, Cahill JA, Tan CW, Berens ME, Han H, Bussey KJ, Von Hoff DD, Hlavacek WS, Posner RG. PMID: 22913808; PMCID: PMC3485121.
      View in: PubMed   Mentions:
    23. Mathematical investigation of how oncogenic ras mutants promote ras signaling. Methods Mol Biol. 2012; 880:69-85. Stites EC, Ravichandran KS. PMID: 23361982.
      View in: PubMed   Mentions:
    24. Mechanistic modeling to investigate signaling by oncogenic Ras mutants. Wiley Interdiscip Rev Syst Biol Med. 2012 Jan-Feb; 4(1):117-27. Stites EC, Ravichandran KS. PMID: 21766467.
      View in: PubMed   Mentions:
    25. Modeling membrane localization: case study of a Ras signaling model. Adv Exp Med Biol. 2010; 680:661-7. Stites EC. PMID: 20865552.
      View in: PubMed   Mentions:
    26. A systems perspective of ras signaling in cancer. Clin Cancer Res. 2009 Mar 01; 15(5):1510-3. Stites EC, Ravichandran KS. PMID: 19208795.
      View in: PubMed   Mentions:
    27. Network analysis of oncogenic Ras activation in cancer. Science. 2007 Oct 19; 318(5849):463-7. Stites EC, Trampont PC, Ma Z, Ravichandran KS. PMID: 17947584.
      View in: PubMed   Mentions:
    Edward's Networks
    Concepts (141)
    Derived automatically from this person's publications.
    _
    Co-Authors (25)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _